10x Genomics (NASDAQ:TXG) Cut to “Hold” at Wall Street Zen

10x Genomics (NASDAQ:TXG) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

A number of other analysts have also weighed in on TXG. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday, August 30th. Bank of America upped their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a “neutral” rating in a report on Thursday, June 26th. Zacks Research lowered shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Friday, September 5th. UBS Group upped their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft set a $14.00 target price on shares of 10x Genomics and gave the stock a “hold” rating in a report on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $13.65.

10x Genomics Trading Down 3.2%

Shares of TXG stock opened at $12.64 on Friday. The stock has a market capitalization of $1.57 billion, a P/E ratio of -18.06 and a beta of 2.00. The firm’s 50 day moving average is $13.21 and its 200 day moving average is $10.81. 10x Genomics has a 12 month low of $6.78 and a 12 month high of $24.38.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.63. The company had revenue of $172.91 million for the quarter, compared to analysts’ expectations of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. 10x Genomics’s revenue was up 12.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. On average, equities analysts predict that 10x Genomics will post -1.43 EPS for the current year.

Insider Activity

In related news, insider Benjamin J. Hindson sold 7,486 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the transaction, the insider owned 440,888 shares of the company’s stock, valued at approximately $6,079,845.52. This trade represents a 1.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Serge Saxonov sold 9,348 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the transaction, the chief executive officer directly owned 945,892 shares in the company, valued at approximately $13,043,850.68. This represents a 0.98% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,149 shares of company stock valued at $539,865. Corporate insiders own 9.39% of the company’s stock.

Hedge Funds Weigh In On 10x Genomics

Several institutional investors and hedge funds have recently made changes to their positions in TXG. Cetera Investment Advisers grew its holdings in 10x Genomics by 22.7% in the 4th quarter. Cetera Investment Advisers now owns 19,898 shares of the company’s stock worth $286,000 after acquiring an additional 3,679 shares during the last quarter. Deutsche Bank AG grew its holdings in 10x Genomics by 35.3% in the 4th quarter. Deutsche Bank AG now owns 10,190 shares of the company’s stock worth $146,000 after acquiring an additional 2,657 shares during the last quarter. Gotham Asset Management LLC bought a new stake in 10x Genomics in the 4th quarter worth $264,000. Jacobs Levy Equity Management Inc. bought a new stake in 10x Genomics in the 4th quarter worth $450,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in 10x Genomics by 37.0% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 159,165 shares of the company’s stock worth $2,286,000 after acquiring an additional 42,950 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.